Target intelligence / Profile preview

MicroRNA 433 (MIR433)

Target
MIR433
Molecular classification
microRNA, Non-coding RNA, Regulatory RNA, Other
01

Overview

MicroRNA 433 (MIR433) is a short non-coding RNA molecule involved in the post-transcriptional regulation of gene expression through mRNA binding and silencing. It is transcribed as part of the imprinted microRNA cluster at chromosomal region 14q32.2 and matures into active forms hsa-miR-433-3p and hsa-miR-433-5p. MIR433 functions predominantly as a tumor suppressor in diverse cancers by inhibiting proliferation, migration, invasion, cell cycle progression, and promoting apoptosis through targeting oncogenic genes such as c-Met, CREB1, HDAC6, and Notch1. Its expression is often silenced epigenetically in cancers via promoter hypermethylation, and restoration of MIR433 levels suppresses tumor progression and EMT processes. Beyond oncology, MIR433 is implicated in neurodegenerative and inflammatory diseases, and is considered both a therapeutic target and a potential biomarker for prognosis and treatment selection.

Other names
hsa-miR-433MIRN433miRNA433mir-433hsa-mir-433-3phsa-mir-433-5p
02

Mechanism of action

Epigenetic modulation of MIR433 expression (e.g., demethylating agents upregulate MIR433); Indirect sensitization to chemotherapy via restoration of MIR433 function; Target gene suppression (e.g., HDAC6, Notch1, CREB1, c-Met)

03

Biological functions

Post-transcriptional regulation of gene expressionCell proliferationApoptosisCell cycle regulationEpithelial–mesenchymal transition (EMT)Signal transduction modulationImmune response regulation
04

Disease associations

Cancer (including bladder, lung, breast, ovarian, esophageal, cervical, glioma, retinoblastoma, osteosarcoma, colorectal, gastric, gallbladder, pancreatic, and cholangiocarcinoma)Neurodegenerative disease (e.g., Parkinson's disease)Inflammation (e.g., Lupus nephritis, bone healing disorders)Cardiovascular disease (e.g., myocardial ischemia-reperfusion injury)Other (context-dependent roles in tissue injury, trauma, and repair)
05

Safety considerations

Off-target effects and systemic delivery challenges for miRNA-based therapeuticsPotential for unintended gene regulation due to broad target range of microRNAsImmune activation or suppression
06

Interacting drugs

Cisplatin (sensitizing tumor cells to chemotherapy)
07

Biomarkers

MIR433 expression levels (prognostic/predictive marker in various cancers and treatment response, e.g. to cisplatin in gastric cancer)DNA methylation status of MIR433 promoter (epigenetic marker for tumor diagnosis/prognosis)

Beyond the preview

Go deeper on MicroRNA 433 (MIR433).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA 433 (MIR433).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call